Testing ER-100 safety for glaucoma or NAION patients
Part of Brain & nervous system, Eyes & vision clinical trials.
This trial tests whether a new drug, ER-100, is safe for people with glaucoma or a sudden optic nerve injury called NAION. It aims to see if the drug can be given without serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 40 and 85 years old.
- You must have clear eye structures and be able to have your pupils dilated for a thorough eye exam.
- If you have glaucoma: you must have open-angle glaucoma with moderate to advanced vision loss and eye pressure below 30 mmHg.
- If you have NAION: you must have had sudden, painless vision loss in one eye within the last 14 days, with optic nerve swelling and vision loss confirmed by tests.
- You must not have certain other eye conditions like severe cataracts, macular problems, or a history of optic neuritis.
- You must not have had eye surgery within the last 3 months, or have uncontrolled diabetes or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new eye drop (QLS-111) to see if it improves blood flow in the back of the eye. It may help people with mild to moderate glaucoma or stable diabetic retinopathy by reducing pressure inside the eye and nourishing the optic nerve.
This trial tests a nose spray medication (cenegermin) for people who recently lost vision due to a specific type of optic nerve damage (NAION). The goal is to see if it can help restore sight when started within two weeks of vision loss.
This trial tests a new drug called FB1001 in people who have sudden vision loss from either a certain type of glaucoma or a different optic nerve condition. Researchers want to see if it can help protect the nerve in your eye and improve recovery.
This study tests an eye drop (G01) for people with primary open-angle glaucoma that is getting worse despite current treatments. It aims to see if G01 can safely slow down or stop the progression of glaucoma.
This Phase 1 study tests whether lab-made stem cells taken from donated umbilical cord are safe for people with NAION. It mainly looks for side effects and safety rather than proving the treatment works.
This trial tests an investigational drug called REGN22530 for people with mild to moderate primary open-angle glaucoma or ocular hypertension (high eye pressure). The goal is to see if it can safely lower eye pressure and protect vision.
Hear when a new Open Angle Glaucoma (OAG) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.